{"filing":{"accession_number":"0001171843-26-004649","cik":"0001801198","ticker":"LEGN","company_name":"Legend Biotech Corp","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"f6k_071426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801198/000117184326004649/f6k_071426.htm"},"events":[{"id":18016,"run_id":16170,"accession_number":"0001171843-26-004649","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Legend Biotech announced preliminary net trade sales of approximately $657 million for CARVYKTI® during the quarter ended June 30, 2026. This is a discrete disclosure of quarterly financial results for a key product, announced on July 15, 2026, and constitutes an earnings release. The sales figure is material to investors assessing the company's commercial performance and revenue trajectory.","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":16697,"accession_number":"0001171843-26-004649","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Legend Biotech announced preliminary net trade sales of approximately $657 million for CARVYKTI® during the quarter ended June 30, 2026. This is a discrete disclosure of quarterly financial results for a key product, announced on July 15, 2026, and constitutes an earnings release. The sales figure is material to investors assessing the company's commercial performance and revenue trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T11:31:38.329578+00:00","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-07-15"}]}